Concordant driver genes included many mutations targeted by cancer drugs, including PIK3CA, EGFR, BRAF, and ALK. Thus, our bank of PDX mouse models can be a useful resource for testing drug efficacy in a preclinical setup. This evidence concerns the gene BRAF and cancer.